Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

EPH Receptor A2 Antikörper

EPHA2 Reaktivität: Human WB, ELISA, IHC Wirt: Maus Monoclonal 1B3C7 unconjugated
Produktnummer ABIN1724651
  • Target Alle EPH Receptor A2 (EPHA2) Antikörper anzeigen
    EPH Receptor A2 (EPHA2)
    Reaktivität
    • 168
    • 127
    • 69
    • 14
    • 6
    • 5
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 177
    • 19
    • 4
    • 1
    Maus
    Klonalität
    • 175
    • 25
    • 1
    Monoklonal
    Konjugat
    • 69
    • 18
    • 10
    • 10
    • 10
    • 10
    • 10
    • 10
    • 9
    • 8
    • 8
    • 7
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    Dieser EPH Receptor A2 Antikörper ist unkonjugiert
    Applikation
    • 117
    • 68
    • 27
    • 23
    • 15
    • 14
    • 13
    • 7
    • 7
    • 7
    • 7
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
    Aufreinigung
    purified
    Immunogen
    Purified recombinant fragment of EphA2 expressed in E. coli.
    Klon
    1B3C7
    Isotyp
    IgM
    Top Product
    Discover our top product EPHA2 Primärantikörper
  • Applikationshinweise
    ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Ascitic fluid containing 0.03 % sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C/-20 °C
    Informationen zur Lagerung
    4°C, -20°C for long term storage
  • Abraham, Knapp, Cheng, Snyder, Mittal, Bangari, Kinch, Wu, Dhariwal, Mohammed: "Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 2, pp. 353-60, (2006) (PubMed).

    Landen, Kinch, Sood: "EphA2 as a target for ovarian cancer therapy." in: Expert opinion on therapeutic targets, Vol. 9, Issue 6, pp. 1179-87, (2005) (PubMed).

  • Target
    EPH Receptor A2 (EPHA2)
    Andere Bezeichnung
    EphA2 (EPHA2 Produkte)
    Synonyme
    ARCC2 antikoerper, CTPA antikoerper, CTPP1 antikoerper, CTRCT6 antikoerper, ECK antikoerper, epha2 antikoerper, MGC89505 antikoerper, AW545284 antikoerper, Eck antikoerper, Myk2 antikoerper, Sek-2 antikoerper, Sek2 antikoerper, id:ibd5152 antikoerper, rtk6 antikoerper, G42 antikoerper, XE10 antikoerper, epha2-A antikoerper, EPH receptor A2 antikoerper, Eph receptor A2 antikoerper, epoxide hydrolase antikoerper, eph receptor A2 a antikoerper, EPH receptor A2 L homeolog antikoerper, EPHA2 antikoerper, Epha2 antikoerper, epha2 antikoerper, ephA2 antikoerper, epha2a antikoerper, epha2.L antikoerper
    Hintergrund

    Description: EPH receptor A2 (EphA2), with 976-amino acid protein (about 107 kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4 and EphB6 are Eph family receptors for Ephrin family ligands. In normal cells, EphA2 negatively regulates cell growth and invasiveness. EphA2 is overexpressed by many human cancers, and is often associated with poor prognostic features. The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers.EphA2 may serve as a novel target for bladder cancer, colonic adenocarcinoma and ovarian cancer therapy.

    Aliases: ECK, EPHA2

    Gen-ID
    1969
    HGNC
    1969
    Pathways
    RTK Signalweg
Sie sind hier:
Kundenservice